MFMariana Lourenço Freire

Mariana Lourenço Freire

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mariana Lourenço Freire has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic accuracy of tests for visceral leishmaniasis caused by Leishmania infantum: A systematic review and meta-analysis

    by Mariana Lourenço Freire, Tália Santana Machado de Assis, Daniel Moreira de Avelar, Ana Rabello, Gláucia Cota, Sarah Nascimento Silva


  • Open Access

    Accuracy of diagnostic strategies for detecting Schistosoma mansoni infection in Brazil: A systematic review and meta-analysis

    by Tália Santana Machado de Assis, Mariana Lourenço Freire, Sarah Nascimento Silva, Daniel Moreira de Avelar, Gláucia Cota, Ana Rabello

    Background: Schistosoma mansoni infection remains a major public health concern in Brazil. Accurate diagnostic methods are essential for monitoring transmission and guiding control and elimination strategies. This systematic review and meta-analysis aimed to assess the performance of diagnostic tests used for S. mansoni infection in Brazil. Methods: Studies conducted in endemic areas of Brazil that used parasitological methods as the reference standard, reported sensitivity and specificity, and were published through October 2024, were included in the analysis. Diagnostic performance was synthesized using univariate and multivariate meta-analyses, and risk of bias was assessed with QUADAS-2. Results: Thirty-three studies were included; most were conducted in Minas Gerais (63%). The main reference standard was Kato-Katz alone (48%) or combined with other parasitological methods (42.4%). Enzyme-linked immunosorbent (ELISA)-SEA results showed higher accuracy than ELISA-SWAP (81% vs 68%), although both exhibited heterogeneity above 80%. Point-of-care circulating cathodic antigen with trace results interpreted as positive (POC-CCA+) or negative (POC-CCA-) showed similar accuracy (70% vs 73%, respectively), with heterogeneity exceeding 80%. For conventional PCR, PCR-ELISA, real-time PCR, and loop-mediated isothermal amplification (LAMP), accuracy ranged from 67% to 82% (heterogeneity: > 90%. In multivariate analysis, conventional PCR had the highest diagnostic odds ratio (DOR: 99.4), followed by PCR-ELISA (DOR: 12.4), whereas the two POC-CCA reading criteria resulted in lower values (trace-positive: 8.5, trace-negative: 6.1). Conclusions: Overall, these observations support the use of combined diagnostic strategies and underscore the need for multicenter, methodologically rigorous studies to strengthen surveillance, control, and elimination efforts for Schistosoma mansoni infection in Brazil.

  • Open Access

    Evaluation of health technology implementation in the Brazilian public health system: a systematic review

    by Mariana Lourenço Freire, Beatriz Prado Noronha, Gláucia Cota, Sarah Nascimento Silva

    The implementation of technologies in the Unified Health System (SUS) faces significant challenges in Brazil due to the diversity of contexts, the specificities of the technologies, and resource limitations. This study aimed to identify and critically describe the theoretical models and strategies adopted, as well as the outcomes most frequently reported in SUS implementation studies. The primary research question was: “How are health technologies implemented within the SUS context, and what outcomes are evaluated?”. A systematic literature search was conducted, followed by independent reviewers’ screening and selection of articles. Studies published up to April 2024 that described the implementation process within the SUS and reported at least one of the following outcomes were included: acceptability, adoption, adequacy, feasibility, fidelity, penetration, implementation cost, and sustainability. Non-original studies or those published in languages other than Portuguese, English, or Spanish were excluded. A total of 45 studies were included, most of which were conducted in the Southeast region (53.0%) and focused on evaluating the implementation of good health practice processes (42.0%), with an emphasis on the perspectives of health professionals. Consolidated implementation frameworks were employed in 60% of the studies, with the framework from the Australian organization Joanna Briggs Institute (JBI) being the most frequently applied (17 studies), followed by the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework (RE-AIM) used in seven studies, and the Consolidated Framework for Implementation Research (CFIR) in three studies. Among the outcomes of interest, adequacy was the most frequently analyzed (66.7%), followed by penetration (24.4%) and fidelity (20.0%). In contrast, the outcomes of implementation cost (4.4%) and sustainability (4.4%) were the least explored. This study highlights the variability in the models and methods used to evaluate the implementation of health technologies in the SUS. The absence of standardized approaches underscores the need for consistent guidelines to guide the implementation process. Future studies should prioritize outcomes that capture the impact of implementation strategies within universal health systems, such as the SUS.


  • Open Access

    Impact of age and immune status on the accuracy of rapid diagnostic tests for visceral leishmaniasis in Brazil

    by Mariana Lourenço Freire, Daniel Moreira de Avelar, Mariana Junqueira Pedras, Líndicy Leidicy Alves, Veronica Cardoso Santos de Faria, Lara Saraiva, Tália Santana Machado de Assis, Dorcas Lamounier Costa, Gláucia Cota

    Background: Visceral leishmaniasis (VL) represents a significant public health concern due to its high case-fatality, which poses the challenge of a timely and accurate diagnosis. Antibody-based rapid diagnostic tests (RDTs) have emerged as a disruptive innovation in recent years, by offering a diagnosis in the field, at low cost, easy to perform and with results in a few minutes. However, their performance can vary across regions and different subgroups, particularly in immunocompromised individuals. This study aimed to assess the accuracy of VL RDTs registered with the Brazilian national regulatory agency, or available through the PAHO strategic fund, considering diverse patient profiles. Methodology/principal findings: Three commercially RDTs were identified LSH Ab Eco Teste, Leishmaniasis VH Bio, and Kalazar Detect and evaluated using a well characterized panel of serum samples (n = 300) from suspected VL patients from different Brazilian regions. Sensitivity, specificity, and accuracy were determined for different patient’s ages and HIV coinfection status. Overall, RDTs exhibited lower sensitivity in children under 3 years old and HIV co-infected individuals compared to those over 3 years without HIV co-infection (p < 0.05). The agreement (Cohen’s kappa coefficient) between observers (reproducibility) and intra-test (repeatability) for all three commercial kits was excellent. Conclusions/significance: While RDTs offer desirable advantages in terms of access to diagnoses, variation on their performance imposes limits on their implementation. The performance of RDTs for VL exhibits significant differences related to age and immune status.


  • Open Access

    Expanding the known geographic range of Leishmania (Mundinia) enriettii: clinical and molecular characterization in naturally infected guinea pigs from southern Brazil

    by Felipe Dutra-Rêgo, Mariana S. Otto, Ana Cristina V.M.R. Lima, Emanuel Caon, Leonardo Gruchouskei, Mariana L. Freire, Marcelo A. Pascoal-Xavier, Edward Oliveira, Fabiana Elias, José Dilermando Andrade Filho

    Three domestic guinea pigs (Cavia porcellus) from Ampére, Paraná State, Brazil, presenting crusted nodular lesions on the pinnae, snout, and digits of all limbs were examined at the University Veterinary Hospital of the Federal University of the Southern Border in February 2023. Cytological evaluation by fine-needle aspiration revealed Leishmania amastigotes within macrophages. Two animals were euthanized for further histopathological, immunohistochemical, parasitological, and molecular investigations. Skin samples exhibited a diffuse mixed inflammatory infiltrate, predominantly histiocytic, with macrophages densely parasitized by amastigotes. Immunohistochemistry (IHC) using an anti-mTXNPx monoclonal antibody confirmed the abundant presence of amastigotes in the skin, providing key diagnostic support. Liver sections showed mild lymphocytic infiltrates, with specific IHC labeling in pericentral hepatocytes indicating antigenic presence despite the absence of visible parasites. Kidneys, lungs, and spleen exhibited mild architectural changes with no detectable amastigotes on microscopy. Promastigote forms were successfully isolated in NNN/LIT medium from one liver sample. Molecular analysis using hsp70-targeted PCR and sequencing confirmed the presence of Leishmania DNA in the skin, spleen, and liver, identifying the species as Leishmania (Mundinia) enriettii. The absence of microscopically visible amastigotes in tissues, despite molecular and immunohistochemical evidence, underscores the value of a multimodal diagnostic approach. This study expands the known geographic distribution of L. enriettii in Paraná State and reinforces the guinea pig’s role as the only confirmed reservoir of this parasite in Brazil.

  • Top Cited Papers
    Open Access

    Diagnosis of human brucellosis: Systematic review and meta-analysis

    by Mariana Lourenço Freire, Tália Santana Machado de Assis, Sarah Nascimento-Silva, Gláucia Cota

    Background: Brucellosis, a widely spread zoonotic disease, poses significant diagnostic challenges due to its non-specific symptoms and underreporting. Timely and accurate diagnosis is crucial for effective patient management and public health control. However, a comprehensive comparative review of available diagnostic tests is lacking. Methodology/Principal findings: This systematic review addressed the following question: ‘What is the accuracy of the available tests to confirm human brucellosis?’ Two independent reviewers examined articles published up to January 2023. The review included original studies reporting symptomatic patients with brucellosis suspicion, through any index test, with sensitivity and/or specificity as outcomes. As exclusion criteria were considered: sample size smaller than 10 patients, studies focusing on complicated brucellosis, and those lacking essential information about index or comparator tests. Sensitivity and specificity were assessed, with consideration for the index test, and ‘culture’ and ‘culture and standard tube agglutination test (SAT)’ were used as reference standards. Bias assessment and certainty of evidence were carried out using the QUADAS-2 and GRADE tools, respectively. A total of 38 studies reporting diagnostic test performance for human brucellosis were included. However, the evidence available is limited, and significant variability was observed among studies. Regarding the reference test, culture and/or SAT are deemed more appropriate than culture alone. Rose Bengal, IgG/IgM ELISA, and PCR exhibited equally high performances, indicating superior overall diagnostic accuracy, with very low certainty of the evidence. Conclusions/Significance: This systematic review underscores the potential of the Rose Bengal test, IgG/IgM ELISA, and PCR as promising diagnostic tools for brucellosis. However, the successful implementation and recommendations for their use should consider the local context and available resources. The findings highlight the pressing need for standardization, improved reporting, and ongoing advancements in test development to enhance the accuracy and accessibility of brucellosis diagnosis.


  • Open Access

    Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis

    by Janaína de Pina Carvalho, Gláucia Cota, Mariana Lourenço Freire, Endi Lanza Galvão, Sarah Nascimento Silva, Tália Santana Machado de Assis

    This study aimed to estimate the cost-effectiveness of four therapeutic approaches available for mucosal leishmaniasis in Brazil: miltefosine, meglumine antimoniate, combined with and without pentoxifylline, and liposomal amphotericin B. The perspective adopted was that of the Brazilian Unified National Health System (SUS). The outcome of interest was “cured patient”, which was analyzed using a decision tree model. Estimates of direct costs and effectiveness were obtained from the scientific literature. Meglumine antimoniate alone was the base comparator strategy; liposomal amphotericin B showed an incremental cost-effectiveness ratio (ICER) of USD 7,409.13 per cured patient, and the combination of meglumine antimoniate with pentoxifylline presented an ICER of USD 85.13. Miltefosine was absolutely dominated, with higher cost and similar effectiveness when compared to meglumine antimoniate. Sensitivity analyses, varying the cost by ±25%, did not change the results. However, when the cost of miltefosine was estimated at less than USD 171.23, this strategy was dominant over meglumine antimoniate alone. The results confirm that treatment with liposomal amphotericin B remains the option with the highest ICER among the approaches analyzed. Miltefosine may be cost-effective based on the variation in the acquisition price, which deserves attention because it is the only available oral option. The non-accounting of other aspects prevent the use of these results immediately to support decision-making, but they point out the need to negotiate the prices of drugs available for mucosal leishmaniasis and indicates the need of encouraging technology transfer or other actions aimed at expanding the performance of the Brazilian national industrial complex.


  • Open Access

    Serology for visceral leishmaniasis: How trusty is the accuracy reported by the manufacturers?

    by Mariana Lourenço Freire, Maria Clara de Oliveira Gonçalves, Allana Carolina Marques da Silva, Gláucia Cota, Ana Rabello, Tália Santana Machado de Assis

    Timely and accurate diagnosis is one of the strategies for managing visceral leishmaniasis (VL). Given the specificities of this infection, which affects different vulnerable populations, the local assessment of the accuracy of the available diagnostic test is a requirement for the good use of resources. In Brazil, performance data are required for test registration with the National Regulatory Agency (ANVISA), but there are no minimum requirements established for performance evaluation. Here, we compared the accuracy reported in the manufacturer's instructions of commercially available VL-diagnostic tests in Brazil, and the accuracies reported in the scientific literature which were obtained after test commercialization. The tests were identified via the electronic database of ANVISA, and their accuracy was obtained from the manufacturer's instructions. A literature search for test accuracy was performed using two databases. A total of 28 VL diagnostic tests were identified through the ANVISA database. However, only 13 presented performance data in the manufacturer's instructions, with five immunoenzymatic tests, three indirect immunofluorescence tests, one chemiluminescence test, and four rapid tests. For most tests, the manufacturers did not provide the relevant information, such as sample size, reference standards, and study site. The literature review identified accuracy data for only 61.5% of diagnostic tests registered in Brazil. These observations confirmed that there are significant flaws in the process of registering health technologies and highlighted one of the reasons for the insufficient control of policies, namely, the use of potentially inaccurate and inappropriate diagnostic tools for a given scenario.


  • Open Access

    Performance differences among commercially available antigen rapid tests for COVID-19 in Brazil

    by Mariana Lourenço Freire, Lindicy Leidicy Alves, Carolina Senra de Souza, Juliana Wilke Saliba, Verônica Faria, Mariana Junqueira Pedras, Nara de Oliveira Carvalho, Gláucia Queiroz Andrade, Ana Rabello, Daniel Moreira Avelar, et al.

    A rapid and accurate diagnosis is a crucial strategy for containing the coronavirus disease (COVID-19) pandemic. Considering the obstacles to upscaling the use of RT–qPCR, rapid tests based on antigen detection (Ag-RDT) have become an alternative to enhance mass testing, reducing the time for a prompt diagnosis and virus spreading. However, the performances of several commercially available Ag-RDTs have not yet been evaluated in several countries. Here, we evaluate the performance of eight Ag-RDTs available in Brazil to diagnose COVID-19. Patients admitted to tertiary hospitals with moderate or mild COVID-19 symptoms and presenting risk factors for severe disease were included. The tests were performed using a masked protocol, strictly following the manufacturer’s recommendations and were compared with RT–qPCR. The overall sensitivity of the tests ranged from 9.8 to 81.1%, and specificity greater than 83% was observed for all the evaluated tests. Overall, slight or fair agreement was observed between Ag-RDTs and RT–PCR, except for the Ag-RDT COVID-19 (Acro Biotech), in which moderate agreement was observed. Lower sensitivity of Ag-RDTs was observed for patients with cycle threshold > 25, indicating that the sensitivity was directly affected by viral load, whereas the effect of the disease duration was unclear. Despite the lower sensitivity of Ag-RDTs compared with RT–qPCR, its easy fulfillment and promptness still justify its use, even at hospital admission. However, the main advantage of Ag-RDTs seems to be the possibility of increasing access to the diagnosis of COVID-19 in patients with a high viral load, allowing immediate clinical management and reduction of infectivity and community transmission.


  • Open Access

    Cost-effectiveness of anti-SARS-CoV-2 antibody diagnostic tests in Brazil

    by Tália Santana Machado de Assis, Mariana Lourenço Freire, Janaína de Pina Carvalho, Ana Rabello, Gláucia Cota

    Background: Although serologic tests for COVID-19 diagnosis are rarely indicated nowadays, they remain commercially available and widely used in Brazil. The objective of this study was to evaluate the cost-effectiveness of anti-SARS-CoV-2antibody diagnostic tests for COVID-19 in Brazil. Methods: Eleven commercially available diagnostic tests, comprising five lateral-flow immunochromatographic assays (LFAs) and six immunoenzymatic assays (ELISA) were analyzed from the perspective of the Brazilian Unified Health System. Results: The direct costs of LFAs ranged from US$ 11.42 to US$ 17.41and of ELISAs, from US$ 6.59 to US$ 10.31. Considering an estimated disease prevalence between 5% and 10%, the anti-SARS-CoV-2 ELISA (IgG) was the most cost-effective test, followed by the rapid One Step COVID-19 Test, at an incremental cost-effectiveness ratio of US$ 2.52 and US$ 1.26 per properly diagnosed case, respectively. Considering only the LFAs, at the same prevalence estimates, two tests, the COVID-19 IgG/IgM and the One Step COVID-19 Test, showed high effectiveness at similar costs. For situations where the estimated probability of disease is 50%, the LFAs are more costly and less effective alternatives. Conclusions: Nowadays there are few indications for the use of serologic tests in the diagnosis of COVID-19 and numerous commercially available tests, with marked differences are observed among them. In general, LFA tests are more cost-effective for estimated low-COVID-19-prevalences, while ELISAs are more cost-effective for high-pretest-probability scenarios.